Cargando…
MRI-Based Radiomic Signature Identifying Secondary Loss of Response to Infliximab in Crohn's Disease
Up to 50% of patients with Crohn's disease (CD) experience secondary loss of response (SLR) to infliximab. Patients with SLR may show clinical signs of iron deficiency as a result of inflammation despite being iron-replete. The magnetic resonance imaging (MRI)-based radiomic index, R2(*), can d...
Autores principales: | Feng, Jing, Feng, Qi, Chen, Yueying, Yang, Tian, Cheng, Saiming, Qiao, Yuqi, Shen, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763017/ https://www.ncbi.nlm.nih.gov/pubmed/35047543 http://dx.doi.org/10.3389/fnut.2021.773040 |
Ejemplares similares
-
A Novel Radiomics Nomogram for the Prediction of Secondary Loss of Response to Infliximab in Crohn’s Disease
por: Chen, Yueying, et al.
Publicado: (2021) -
Infliximab response associates with radiologic findings in bio-naïve Crohn’s disease
por: Yueying, Chen, et al.
Publicado: (2023) -
Development and validation of a clinical radiomics nomogram to predict secondary loss of response to infliximab in Crohn's disease patients
por: Zhu, Chao, et al.
Publicado: (2023) -
Body composition parameters correlate with the endoscopic severity in Crohn’s disease patients treated with infliximab
por: Tang, Wuli, et al.
Publicado: (2023) -
Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn’s Disease Patients
por: Chen, Yueying, et al.
Publicado: (2021)